Find policies, billing codes, payers, states, and providers
CPT 87624: High-Risk HPV Nucleic Acid Detection, Pooled Result
CPT code 87624 represents a laboratory molecular test for detection of high-risk human papillomavirus (HPV) using nucleic acid amplification and reporting a pooled result. This test is a cornerstone of cervical cancer screening and HPV-related disease surveillance nationwide because identification of high-risk HPV types guides clinical follow-up and preventive strategies.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of CPT code 87624, including clinical context for use, typical sites of service, and the kinds of benchmarks and policy elements that influence coverage and billing practices. The publication summarizes reimbursement benchmarks, common billing modifiers, and coding considerations relevant to laboratory and hospital billing teams.
The content also outlines implications for laboratory service lines and payer interactions, highlights where policy updates commonly affect reimbursement, and provides a framework for interpreting payer-specific coverage language. Data not available in the input is noted where applicable.
Customize your policy alerts
Sign up for cpt 87624 policy alerts
Get alerted when payer policies referencing 87624 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 87624 describes a laboratory test that detects human papillomavirus (HPV) using nucleic acid detection methods for high-risk HPV types, reported as a pooled result. The procedure is performed by a laboratory analyst and produces a qualitative outcome indicating presence or absence of target high-risk HPV DNA.
-
Service type: Molecular diagnostic test (nucleic acid detection) for high-risk HPV
-
Typical site of service: Clinical laboratory or hospital laboratory setting